Sagimet Biosciences Changes Independent Auditor

TL;DR

Sagimet swapped auditors from EY to PwC, effective Aug 18.

AI Summary

Sagimet Biosciences Inc. announced on August 18, 2025, a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm, replacing Ernst & Young LLP. This change is effective immediately.

Why It Matters

A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors will monitor.

Risk Assessment

Risk Level: low — The filing solely reports a change in the company's independent auditor, which is a routine administrative event.

Key Players & Entities

• Sagimet Biosciences Inc. (company) — Registrant
• PricewaterhouseCoopers LLP (company) — New independent registered public accounting firm
• Ernst & Young LLP (company) — Former independent registered public accounting firm
• August 18, 2025 (date) — Effective date of auditor change

FAQ

Key Financial Figures

• $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G

Filing Documents

• tm2524100d1_8k.htm (8-K) — 30KB
• tm2524100d1_ex16-1.htm (EX-16.1) — 4KB
• 0001104659-25-081630.txt ( ) — 199KB
• sgmt-20250818.xsd (EX-101.SCH) — 3KB
• sgmt-20250818_lab.xml (EX-101.LAB) — 33KB
• sgmt-20250818_pre.xml (EX-101.PRE) — 22KB
• tm2524100d1_8k_htm.xml (XML) — 4KB

01

Item 4.01. Changes in Registrant's Certifying Accountant. On August 18, 2025, the Audit Committee of the Board of Directors (the "Board") of Sagimet Biosciences Inc. (the "Company") recommended and the Board approved (i) the appointment of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm for the Touche LLP ("Deloitte") as the Company's independent registered public accounting firm, effective immediately. The audit reports of Deloitte on the Company's financial statements as of December 31, 2024 and December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles. Furthermore, during the two most recent fiscal years ended December 31, 2024 and December 31, 2023, and the subsequent interim period through August 18, 2025, there were no disagreements with Deloitte on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Deloitte, would have caused it to make a reference in connection with its opinion to the subject matter of the disagreement or reportable events as defined in Item 304(a)(1)(v) of Regulation S-K. During the two most recent fiscal years ended December 31, 2024 and December 31, 2023, and the subsequent interim period through August 18, 2025, KPMG has not been engaged as either the principal accountant to audit the Company's financial statements, or as an independent accountant to audit a significant subsidiary of the Company. During the two most recent fiscal years, ended December 31, 2024 and December 31, 2023, and the subsequent interim period through August 18, 2025, neither the Company nor anyone on the Company's behalf consulted KPMG regarding (i) the application of accountin

01

Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit Number Description 16.1 Letter to the Securities and Exchange Commission from Deloitte & Touche LLP, dated August 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: August 22, 2025 By: /s/ David Happel David Happel Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR